| Abstrakt: |
A recent study from Lenox Hill Hospital in New York City has presented new data on mesenchymal stem cells. The research focuses on the treatment of articular cartilage lesions, which have become increasingly treatable with joint preservation procedures. The study discusses three new options for addressing these defects, including Agili-C, Cartistem, and a one-stage procedure utilizing autologous chondrons combined with allogeneic mesenchymal stem cells. These treatments offer potential solutions for knee cartilage defects and have shown safety and efficacy in clinical trials. For more information, readers can refer to the article "Novel Treatment Options for Knee Cartilage Defects in 2023" in the Sports Medicine and Arthroscopy Review. [Extracted from the article] |
